Filippo Montemurro: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world

Filippo Montemurro, Senior Medical Director at F. Hoffmann La Roche, shared a post on LinkedIn:

“I am proud to share the publication of my recent work with the outstanding Gruppo Italiano Mammella (GIM). Describing attrition in metastatic cancers is valuable for oncologists because it helps address a critical clinical question: “If this patient progresses on the current treatment, what are the chances she/he will be able to receive subsequent therapy?”

Understanding attrition has several practical benefits that we address in this paper. Thanks to co-workers and in particular to Eva Blondeaux for her fantastic competence and committment.”

Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world

Authors: Eva Blondeaux et al.